In the proliferation centers, CLL cells receive essential signals for survival and proliferation including the BCR and NFκB activation [38, 39], and the success of BCR inhibition in CLL treatment has been proven to rely on their capacity to interfere with the CLL cell relocalization. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.